DVAX
Dynavax Technologies Corp.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Market Cap: 1.65 Billion
Primary Exchange: NASDAQ
Website: http://www.dynavax.com/
Shares Outstanding: 129 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.7469112942523729
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 3200 trading days
From: 2013-01-10 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2014-11-10 | 10.0 | 1.0 | 10.0 |